You just read:

VistaGen Therapeutics Receives FDA Clearance of IND for Phase 2 Clinical Study of AV-101 as a Potential Treatment of Dyskinesia in Parkinson's Disease Patients

News provided by

VistaGen Therapeutics

Jan 30, 2020, 08:30 ET